Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype

被引:6
作者
Harrington, Patrick [1 ,2 ]
Dillon, Richard [1 ,3 ]
Radia, Deepti [1 ]
McLornan, Donal [1 ,2 ]
Woodley, Claire [1 ]
Asirvatham, Susan [1 ]
Raj, Kavita [1 ]
Curto-Garcia, Natalia [1 ]
Saunders, Jamie [1 ]
Kordasti, Shahram [1 ,2 ]
Harrison, Claire [1 ,2 ]
de Lavallade, Hugues [1 ,2 ]
机构
[1] Guys & St Thomas NHS Fdn Trust, Dept Clin Haematol, London, England
[2] Kings Coll London, Sch Canc & Pharmaceut Sci, London, England
[3] Kings Coll London, Dept Med & Mol Genet, London, England
关键词
CML; immune checkpoint; inflammation; T cell; T-cell exhaustion; Treg; CHRONIC MYELOGENOUS LEUKEMIA; IMATINIB DISCONTINUATION; MOLECULAR RESPONSE; CML PATIENTS; INTERFERON; ALPHA;
D O I
10.1111/bjh.18302
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The search for novel targets in chronic myeloid leukaemia (CML) is ongoing, to improve treatment efficacy in refractory disease and increase eligibility for tyrosine kinase inhibitor (TKI) discontinuation. Increased frequency of Tregs and effector Tregs was evident at diagnosis, together with increased expression of T-cell exhaustion markers, including in regulatory T cells at diagnosis and in patients with refractory disease. Plasma analysis revealed significantly increased levels of cytokines including tumour necrosis factor (TNF)-a and interleukin (IL)-6 at diagnosis, in keeping with a pro-inflammatory state prior to treatment. We hence demonstrate T-cell exhaustion and a pro-inflammatory state at diagnosis in CML, likely secondary to leukaemia-associated antigenic overload associated with increased disease burden.
引用
收藏
页码:1011 / 1015
页数:5
相关论文
共 24 条
[1]   Tumor-necrosis factor is a master of T cell exhaustion [J].
Baxter, Amy E. ;
Kaufmann, Daniel E. .
NATURE IMMUNOLOGY, 2016, 17 (05) :476-478
[2]   Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML [J].
Bruck, Oscar ;
Blom, Sami ;
Dufva, Olli ;
Turkki, Riku ;
Chheda, Himanshu ;
Ribeiro, Antonio ;
Kovanen, Panu ;
Aittokallio, Tero ;
Koskenvesa, Perttu ;
Kallioniemi, Olli ;
Porkka, Kimmo ;
Pellinen, Teijo ;
Mustjoki, Satu .
LEUKEMIA, 2018, 32 (07) :1643-1656
[3]   Therapeutic targeting of the inflammasome in myeloid malignancies [J].
Chakraborty, Samarpana ;
Shapiro, Lauren C. ;
de Oliveira, Sofia ;
Rivera-Pena, Bianca ;
Verma, Amit ;
Shastri, Aditi .
BLOOD CANCER JOURNAL, 2021, 11 (09)
[4]   Enhanced suppressor function of TIM-3+FoxP3+ regulatory T cells [J].
Gautron, Anne-Sophie ;
Dominguez-Villar, Margarita ;
de Marcken, Marine ;
Hafler, David A. .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2014, 44 (09) :2703-2711
[5]   Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML [J].
Harrington, Patrick ;
Dillon, Richard ;
Radia, Deepti H. ;
McLornan, Donal P. ;
Rousselot, Philippe ;
Rezvani, Katayoun ;
Kordasti, Shahram ;
Harrison, Claire ;
de Lavallade, Hugues .
BLOOD, 2020, 136
[6]   What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia? [J].
Harrington, Patrick ;
Radia, Deepti ;
de Lavallade, Hugues .
EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (03) :213-222
[7]   Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape [J].
Hsieh, Ya-Ching ;
Kirschner, Kristina ;
Copland, Mhairi .
LEUKEMIA, 2021, 35 (05) :1229-1242
[8]   CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors [J].
Hughes, Amy ;
Clarson, Jade ;
Tang, Carine ;
Vidovic, Ljiljana ;
White, Deborah L. ;
Hughes, Timothy P. ;
Yong, Agnes S. M. .
BLOOD, 2017, 129 (09) :1166-1176
[9]   Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia [J].
Ilander, M. ;
Olsson-Stromberg, U. ;
Schlums, H. ;
Guilhot, J. ;
Bruck, O. ;
Lahteenmaki, H. ;
Kasanen, T. ;
Koskenvesa, P. ;
Soderlund, S. ;
Hoglund, M. ;
Markevarn, B. ;
Sjalander, A. ;
Lotfi, K. ;
Dreimane, A. ;
Lubking, A. ;
Holm, E. ;
Bjoreman, M. ;
Lehmann, S. ;
Stenke, L. ;
Ohm, L. ;
Gedde-Dahl, T. ;
Majeed, W. ;
Ehrencrona, H. ;
Koskela, S. ;
Saussele, S. ;
Mahon, F-X ;
Porkka, K. ;
Hjorth-Hansen, H. ;
Bryceson, Y. T. ;
Richter, J. ;
Mustjoki, S. .
LEUKEMIA, 2017, 31 (05) :1108-1116
[10]   Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial [J].
Imagawa, Jun ;
Tanaka, Hideo ;
Okada, Masaya ;
Nakamae, Hirohisa ;
Hino, Masayuki ;
Murai, Kazunori ;
Ishida, Yoji ;
Kumagai, Takashi ;
Sato, Seiichi ;
Ohashi, Kazuteru ;
Sakamaki, Hisashi ;
Wakita, Hisashi ;
Uoshima, Nobuhiko ;
Nakagawa, Yasunori ;
Minami, Yosuke ;
Ogasawara, Masahiro ;
Takeoka, Tomoharu ;
Akasaka, Hiroshi ;
Utsumi, Takahiko ;
Uike, Naokuni ;
Sato, Tsutomu ;
Ando, Sachiko ;
Usuki, Kensuke ;
Morita, Satoshi ;
Sakamoto, Junichi ;
Kimura, Shinya .
LANCET HAEMATOLOGY, 2015, 2 (12) :E528-E535